Display options
Cite
Badr-Eldin SM, Alhakamy NA, Fahmy UA, et al. Cytotoxic and Pro-Apoptotic Effects of a Sub-Toxic Concentration of Fluvastatin on OVCAR3 Ovarian Cancer Cells After its Optimized Formulation to Melittin Nano-Conjugates. Front Pharmacol. 2021;11:642171doi: 10.3389/fphar.2020.642171.
Badr-Eldin, S. M., Alhakamy, N. A., Fahmy, U. A., Ahmed, O. A. A., Asfour, H. Z., Althagafi, A. A., Aldawsari, H. M., Rizg, W. Y., Mahdi, W. A., Alghaith, A. F., Alshehri, S., Caraci, F., & Caruso, G. (2020). Cytotoxic and Pro-Apoptotic Effects of a Sub-Toxic Concentration of Fluvastatin on OVCAR3 Ovarian Cancer Cells After its Optimized Formulation to Melittin Nano-Conjugates. Frontiers in pharmacology, 11642171. https://doi.org/10.3389/fphar.2020.642171
Badr-Eldin, Shaimaa M, et al. "Cytotoxic and Pro-Apoptotic Effects of a Sub-Toxic Concentration of Fluvastatin on OVCAR3 Ovarian Cancer Cells After its Optimized Formulation to Melittin Nano-Conjugates." Frontiers in pharmacology vol. 11 (2020): 642171. doi: https://doi.org/10.3389/fphar.2020.642171
Badr-Eldin SM, Alhakamy NA, Fahmy UA, Ahmed OAA, Asfour HZ, Althagafi AA, Aldawsari HM, Rizg WY, Mahdi WA, Alghaith AF, Alshehri S, Caraci F, Caruso G. Cytotoxic and Pro-Apoptotic Effects of a Sub-Toxic Concentration of Fluvastatin on OVCAR3 Ovarian Cancer Cells After its Optimized Formulation to Melittin Nano-Conjugates. Front Pharmacol. 2021 Feb 03;11:642171. doi: 10.3389/fphar.2020.642171. eCollection 2020. PMID: 33633571; PMCID: PMC7901935.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2021 Feb 03;11:642171. doi: 10.3389/fphar.2020.642171. eCollection 2020.

Cytotoxic and Pro-Apoptotic Effects of a Sub-Toxic Concentration of Fluvastatin on OVCAR3 Ovarian Cancer Cells After its Optimized Formulation to Melittin Nano-Conjugates.

Frontiers in pharmacology

Shaimaa M Badr-Eldin, Nabil A Alhakamy, Usama A Fahmy, Osama A A Ahmed, Hani Z Asfour, Abdulhamid A Althagafi, Hibah M Aldawsari, Waleed Y Rizg, Wael A Mahdi, Adel F Alghaith, Sultan Alshehri, Filippo Caraci, Giuseppe Caruso

Affiliations

  1. Department of Pharmaceutics, King Abdulaziz University, Jeddah, Saudi Arabia.
  2. Department of Pharmaceutics and Industrial Pharmacy, Cairo University, Cairo, Egypt.
  3. Advanced Drug Delivery Research Group, King Abdulaziz University, Jeddah, Saudi Arabia.
  4. Center of Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah, Saudi Arabia.
  5. Mohamed Saeed Tamer Chair for Pharmaceutical Industries, King Abdulaziz University, Jeddah, Saudi Arabia.
  6. Department of Medical Microbiology and Parasitology, King Abdulaziz University, Jeddah, Saudi Arabia.
  7. Department of Clinical Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
  8. Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
  9. Department of Pharmaceutical Sciences, College of Pharmacy, Almaarefa University, Riyadh, Saudi Arabia.
  10. Oasi Research Institute-IRCCS, Troina, Italy.
  11. Department of Drug and Health Sciences, University of Catania, Catania, Italy.

PMID: 33633571 PMCID: PMC7901935 DOI: 10.3389/fphar.2020.642171

Abstract

Fluvastatin (FLV) is a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor often used to lower total and low-density lipoprotein (LDL) cholesterol and for the prevention of adverse cardiovascular events. This drug as well as melittin (MEL), the major component of honeybee venom (

Copyright © 2021 Badr-Eldin, Alhakamy, Fahmy, Ahmed, Asfour, Althagafi, Aldawsari, Rizg, Mahdi, Alghaith, Alshehri, Caraci and Caruso.

Keywords: apoptosis; cytotoxicity; fluvastatin; melittin; nano-conjugates; ovarian cancer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Circ Res. 2019 Jan 18;124(2):328-350 - PubMed
  2. Cardiovasc Surg. 2003 Feb;11(1):52-60 - PubMed
  3. Indian J Cancer. 2014 Mar;51 Suppl 3:e72-6 - PubMed
  4. Breast Cancer Res Treat. 2008 Jun;109(3):573-9 - PubMed
  5. Curr Protein Pept Sci. 2019;20(3):240-250 - PubMed
  6. PLoS One. 2017 Dec 19;12(12):e0189233 - PubMed
  7. Cancer Cell Int. 2013 Nov 08;13(1):111 - PubMed
  8. 3 Biotech. 2020 Mar;10(3):133 - PubMed
  9. J Adv Res. 2020 May 01;24:281-290 - PubMed
  10. Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):737-746 - PubMed
  11. Cochrane Database Syst Rev. 2018 Mar 06;3:CD012282 - PubMed
  12. Indian J Exp Biol. 2010 Dec;48(12):1167-74 - PubMed
  13. Nutr Cancer. 2012;64(2):173-97 - PubMed
  14. Curr Pharm Des. 2009;15(5):467-78 - PubMed
  15. Braz J Med Biol Res. 2020 Dec 18;54(2):e9017 - PubMed
  16. Eur Heart J. 2018 Jul 14;39(27):2526-2539 - PubMed
  17. J Clin Invest. 2009 Sep;119(9):2830-42 - PubMed
  18. Clin Exp Pharmacol Physiol. 2002 Aug;29(8):673-8 - PubMed
  19. Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):e38-e81 - PubMed
  20. Biomolecules. 2020 Feb 06;10(2): - PubMed
  21. Gynecol Oncol. 2010 Jan;116(1):109-16 - PubMed
  22. J Pharmacol Exp Ther. 2020 Jul;374(1):104-112 - PubMed
  23. Arch Gynecol Obstet. 2017 Dec;296(6):1043-1053 - PubMed
  24. Mol Cell Biochem. 2017 Jan;425(1-2):85-93 - PubMed
  25. J Natl Cancer Inst. 2011 Oct 5;103(19):1461-8 - PubMed
  26. Molecules. 2016 Mar 02;21(3):297 - PubMed
  27. AAPS PharmSciTech. 2018 Nov;19(8):3454-3461 - PubMed
  28. Cell Immunol. 2005 Jun;235(2):136-44 - PubMed
  29. Sci Rep. 2019 Jul 3;9(1):9632 - PubMed
  30. Nat Rev Drug Discov. 2019 Jan;18(1):41-58 - PubMed
  31. Antibiotics (Basel). 2020 Aug 14;9(8): - PubMed
  32. Pharmaceutics. 2019 Dec 16;11(12): - PubMed
  33. Cancer Med. 2019 Nov;8(16):7018-7031 - PubMed
  34. Nat Commun. 2018 Aug 28;9(1):3490 - PubMed
  35. Cancer Lett. 2007 Jun 8;250(2):220-8 - PubMed
  36. PLoS One. 2017 May 22;12(5):e0178278 - PubMed
  37. Breast Cancer Res Treat. 2010 Jan;119(1):137-44 - PubMed
  38. Molecules. 2019 Mar 07;24(5): - PubMed
  39. Pharmaceuticals (Basel). 2020 Jul 15;13(7): - PubMed
  40. Pharmaceuticals (Basel). 2020 Oct 21;13(10): - PubMed
  41. PLoS One. 2017 Jun 7;12(6):e0178930 - PubMed
  42. JAMA. 2020 Feb 18;323(7):646-655 - PubMed
  43. Breast Cancer (Dove Med Press). 2017 Dec 01;9:559-565 - PubMed
  44. Asian Pac J Cancer Prev. 2018 Dec 25;19(12):3427-3434 - PubMed
  45. Biopolymers. 1992 Aug;32(8):981-92 - PubMed
  46. NPJ Precis Oncol. 2020 Sep 1;4:24 - PubMed
  47. Nano Lett. 2014 Jan 8;14(1):83-8 - PubMed
  48. Pharmaceutics. 2020 Jun 27;12(7): - PubMed
  49. Surg Clin North Am. 2008 Apr;88(2):285-99, vi - PubMed
  50. Int J Cancer. 2019 Mar 1;144(5):991-1000 - PubMed
  51. Front Pharmacol. 2018 Oct 31;9:1230 - PubMed
  52. J Phys Chem B. 2016 May 5;120(17):3993-4002 - PubMed
  53. Pharmaceutics. 2020 Oct 11;12(10): - PubMed
  54. Int J Cancer. 2016 Sep 15;139(6):1281-8 - PubMed
  55. Int J Cardiol. 2012 Apr 5;156(1):55-61 - PubMed
  56. J Cell Mol Med. 2001 Oct-Dec;5(4):378-87 - PubMed
  57. Cancers (Basel). 2019 Aug 03;11(8): - PubMed
  58. Gynecol Oncol. 2014 Nov;135(2):333-41 - PubMed
  59. Pharmaceutics. 2020 Apr 11;12(4): - PubMed
  60. J Cell Mol Med. 2020 Jan;24(1):655-670 - PubMed
  61. Tumour Biol. 2016 Mar;37(3):3017-24 - PubMed

Publication Types